Soleno Therapeutics Set to Join Russell 3000® Index

Core Points - Soleno Therapeutics, Inc. is set to join the Russell 3000® Index effective July 1, 2024, marking a significant milestone for the company [1][2] - The inclusion in the Russell indexes reflects the progress made in advancing its lead candidate DCCR (diazoxide choline) extended-release tablets through clinical development [2] - The Russell US Indexes reconstitution captures the 4,000 largest US stocks ranked by total market capitalization, with membership in the Russell 3000® Index providing automatic inclusion in the Russell 1000® or Russell 2000® Indexes [2] Company Overview - Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases, with its lead candidate DCCR aimed at treating Prader-Willi syndrome (PWS) [4] - DCCR has recently completed its Phase 3 development program to support a planned NDA submission [4] Industry Context - Russell indexes are widely utilized by investment managers and institutional investors for index funds and as benchmarks for active investment strategies, with approximately $10.5 trillion in assets benchmarked against these indexes as of December 2023 [3]